Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)

Narikazu Boku(Tokyo Medical University), Atsushi Ohtsu(National Cancer Center Hospital East), Kuniaki Shirao(Shizuoka Cancer Center), Takehiko Doi(National Center for Geriatrics and Gerontology), Hiroshi Saito(St. Marianna University School of Medicine), Akira Sawaki(Aichi Cancer Center), Akiharu Kimura(Shizuoka Cancer Center), Wasaburo Koizumi(Kitasato University), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Suguru Yamamoto(Niigata University)
Journal of Clinical Oncology
June 20, 2007
10.1200/jco.2007.25.18_suppl.lba4513
Cited by 158

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632